Thanks for sharing your thoughts! While I’m obviously sad that you’ve updated negatively, this exchange has been very helpful for me to reflect on how to communicate my level of confidence in these treatments, especially given the little data we have from RCTs specifically. The total evidence still looks overall highly compelling to me (I wouldn’t be working on this ~full time otherwise), but I’ll work on improving my communication (and generating more scientific evidence).
The main thing I’d like to say is that I’m really not committed to psychedelics as an intervention (since you brought up the lobbyist language), and I’m particularly excited and hopeful about non-hallucinogenic analogues (such as BOL-148 and Conjugated Psilocin), as well as about non-pharmaceutical interventions, which we’re also exploring. Ultimately, I just want patients to have universal access to treatments that safely and effectively prevent or abort their attacks. Currently, I sincerely believe those happen to be indoleamines.
If the effect is really as strong as claimed, you wouldn’t even need 100 patients for an RCT. Perhaps clusterfree could even make this happen faster
Absolutely agree, and we’re actively thinking about how to do this!
Thanks for sharing your thoughts! While I’m obviously sad that you’ve updated negatively, this exchange has been very helpful for me to reflect on how to communicate my level of confidence in these treatments, especially given the little data we have from RCTs specifically. The total evidence still looks overall highly compelling to me (I wouldn’t be working on this ~full time otherwise), but I’ll work on improving my communication (and generating more scientific evidence).
The main thing I’d like to say is that I’m really not committed to psychedelics as an intervention (since you brought up the lobbyist language), and I’m particularly excited and hopeful about non-hallucinogenic analogues (such as BOL-148 and Conjugated Psilocin), as well as about non-pharmaceutical interventions, which we’re also exploring. Ultimately, I just want patients to have universal access to treatments that safely and effectively prevent or abort their attacks. Currently, I sincerely believe those happen to be indoleamines.
Absolutely agree, and we’re actively thinking about how to do this!